134 related articles for article (PubMed ID: 23944905)
21. Tafluprost: a novel prostaglandin analog for treatment of glaucoma.
Pantcheva MB; Seibold LK; Awadallah NS; Kahook MY
Adv Ther; 2011 Sep; 28(9):707-15. PubMed ID: 21858491
[TBL] [Abstract][Full Text] [Related]
22. Twenty-four-hour efficacy of preservative-free tafluprost for open-angle glaucoma patients, assessed by home intraocular pressure (Icare-ONE) and blood-pressure monitoring.
Cho SY; Kim YY; Yoo C; Lee TE
Jpn J Ophthalmol; 2016 Jan; 60(1):27-34. PubMed ID: 26411460
[TBL] [Abstract][Full Text] [Related]
23. A phase II study on the duration and stability of the intraocular pressure-lowering effect and tolerability of Tafluprost compared with latanoprost.
Traverso CE; Ropo A; Papadia M; Uusitalo H
J Ocul Pharmacol Ther; 2010 Feb; 26(1):97-104. PubMed ID: 20148656
[TBL] [Abstract][Full Text] [Related]
24. Long-term effect of BAK-free travoprost on ocular surface and intraocular pressure in glaucoma patients after transition from latanoprost.
Aihara M; Otani S; Kozaki J; Unoki K; Takeuchi M; Minami K; Miyata K
J Glaucoma; 2012 Jan; 21(1):60-4. PubMed ID: 21278589
[TBL] [Abstract][Full Text] [Related]
25. Comparison of corneal safety and intraocular pressure-lowering effect of tafluprost ophthalmic solution with other prostaglandin ophthalmic solutions.
Kumagami T; Wakiyama H; Kusano M; Kajiyama A; Miura Y; Uematsu M; Yoneda A; Kurihara J; Suzuma K; Kitaoka T
J Ocul Pharmacol Ther; 2014 May; 30(4):340-5. PubMed ID: 24576066
[TBL] [Abstract][Full Text] [Related]
26. Prospective observational post-marketing study of tafluprost for glaucoma and ocular hypertension: short-term efficacy and safety.
Kuwayama Y; Nomura A
Adv Ther; 2014 Apr; 31(4):461-71. PubMed ID: 24615289
[TBL] [Abstract][Full Text] [Related]
27. From benzalkonium chloride-preserved Latanoprost to Polyquad-preserved Travoprost: a 6-month study on ocular surface safety and tolerability.
Rossi GC; Scudeller L; Rolle T; Pasinetti GM; Bianchi PE
Expert Opin Drug Saf; 2015 May; 14(5):619-23. PubMed ID: 25759110
[TBL] [Abstract][Full Text] [Related]
28. In vivo confocal microscopy analyses of corneal microstructural changes in a prospective study of collagen cross-linking in keratoconus.
Jordan C; Patel DV; Abeysekera N; McGhee CN
Ophthalmology; 2014 Feb; 121(2):469-74. PubMed ID: 24183340
[TBL] [Abstract][Full Text] [Related]
29. [The effects of ocular hypotensive drugs on the cornea: an in vivo analysis with confocal microscopy].
Fernández Jiménez-Ortiz H; Toledano Fernández N; Fernández Escamez CS; Perucho Martinez S; Crespo Carballés MJ
Arch Soc Esp Oftalmol; 2013 Nov; 88(11):423-32. PubMed ID: 24157320
[TBL] [Abstract][Full Text] [Related]
30. Tafluprost: the first preservative-free prostaglandin to treat open-angle glaucoma and ocular hypertension.
Swymer C; Neville MW
Ann Pharmacother; 2012 Nov; 46(11):1506-10. PubMed ID: 23092867
[TBL] [Abstract][Full Text] [Related]
31. Effect of tafluprost 0.0015% on central corneal thickness in patients with primary open-angle glaucoma.
Panos GD; Konstantinidis A; Mendrinos E; Kozobolis V; Perente I; Gatzioufas Z
Curr Eye Res; 2013 Sep; 38(9):977-82. PubMed ID: 23713521
[TBL] [Abstract][Full Text] [Related]
32. Decreased keratocyte density and central corneal thickness in primary open-angle glaucoma patients undergoing treatment with topical prostaglandin analogues.
Kocabeyoglu S; Mocan MC; Irkec M
Indian J Ophthalmol; 2015 Jan; 63(1):15-9. PubMed ID: 25686056
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and tolerability of preservative-free 0.0015% tafluprost in glaucoma patients: a prospective crossover study.
Lee W; Lee S; Bae H; Kim CY; Seong GJ
BMC Ophthalmol; 2017 Apr; 17(1):61. PubMed ID: 28454526
[TBL] [Abstract][Full Text] [Related]
34. Preservative-free tafluprost/timolol fixed combination: a new opportunity in the treatment of glaucoma.
Konstas AG; Holló G
Expert Opin Pharmacother; 2016 Jun; 17(9):1271-83. PubMed ID: 27123557
[TBL] [Abstract][Full Text] [Related]
35. [Efficacy and tolerability of preservative-free tafluprost 0.0015 % in the treatment of glaucoma and ocular hypertension].
Karhanová M; Mlčák P; Fryšák Z; Marešová K
Cesk Slov Oftalmol; 2012 Oct; 68(4):150-5. PubMed ID: 23214487
[TBL] [Abstract][Full Text] [Related]
36. Central corneal thickness and measured IOP response to topical ocular hypotensive medication in the Ocular Hypertension Treatment Study.
Brandt JD; Beiser JA; Gordon MO; Kass MA;
Am J Ophthalmol; 2004 Nov; 138(5):717-22. PubMed ID: 15531304
[TBL] [Abstract][Full Text] [Related]
37. Tafluprost Ophthalmic Solution 0.0015 %: A Review in Glaucoma and Ocular Hypertension.
Keating GM
Clin Drug Investig; 2016 Jun; 36(6):499-508. PubMed ID: 27225879
[TBL] [Abstract][Full Text] [Related]
38. [Corneal sensitivity in patients treated medically for glaucoma or ocular hypertension].
Van Went C; Alalwani H; Brasnu E; Pham J; Hamard P; Baudouin C; Labbé A
J Fr Ophtalmol; 2011 Dec; 34(10):684-90. PubMed ID: 22093372
[TBL] [Abstract][Full Text] [Related]
39. Comparison of ocular hypotensive effect and safety of brinzolamide and timolol added to latanoprost.
Miura K; Ito K; Okawa C; Sugimoto K; Matsunaga K; Uji Y
J Glaucoma; 2008; 17(3):233-7. PubMed ID: 18414111
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of Corneal Microstructure in Pseudoexfoliation Syndrome and Glaucoma: In Vivo Scanning Laser Confocal Microscopic Study.
Yüksel N; Emre E; Pirhan D
Curr Eye Res; 2016; 41(1):34-40. PubMed ID: 25612165
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]